Client Overview
A U.S.-China-based biopharmaceutical company required specialized China Regulatory Affairs and NMPA inspection support for a blood-derived therapy classified as a high-risk biological product. The company needed assistance with Regulatory dossier preparation, overseas on-site inspection readiness, audit coordination, Health Authority communication, and compliance risk mitigation to support continued market authorization and Regulatory compliance in China.
Background
As part of China's Regulatory oversight for high-risk biological products, the National Medical Products Administration (NMPA) selected the client's blood-derived product for an overseas on-site inspection. Such inspections are a critical component of China's Regulatory review process for certain biologics and blood products and can directly impact market authorization status.
The client required an experienced Regulatory partner capable of coordinating global inspection activities, preparing inspection-ready documentation, supporting interactions with NMPA officials, and ensuring compliance with evolving Chinese Regulatory expectations for blood-derived and biologic products.
Services in Scope
NMPA Inspection Readiness and Regulatory Support
Regulatory Dossier Preparation and Documentation Review
Overseas On-Site Inspection Coordination
Audit Planning and Regulatory Operations Management
Bilingual Regulatory Communication Support
Health Authority Query and Issue Resolution Support
Compliance Risk Assessment and Mitigation
Market Authorization and Regulatory Compliance Support
Challenge
High-Risk Product Classification The blood-derived therapy was classified as a high-risk biological product by the NMPA, triggering an overseas Regulatory inspection and increasing scrutiny throughout the review process.
Stringent NMPA Regulatory Expectations Any misalignment with inspection requirements, documentation standards, or GMP expectations could have resulted in Regulatory delays, inspection findings, or loss of market qualification in China.
Complex Global Inspection Coordination Managing communication, logistics, documentation, and stakeholder alignment across multiple international locations and NMPA officials required extensive Regulatory project management and operational oversight.
Real-Time Regulatory Communication Requirements The inspection process required immediate bilingual communication and issue resolution support to address Regulatory questions and ensure alignment during audit activities.
Solution
1
Regulatory Dossier Preparation
Prepared and reviewed the complete Regulatory dossier to align with NMPA inspection expectations and support audit readiness.
2
Overseas Inspection Coordination
Managed scheduling, planning, and execution of the overseas on-site inspection while coordinating activities between global stakeholders and NMPA officials.
3
Real-Time Bilingual Regulatory Support
Provided bilingual communication support during the inspection process to facilitate seamless discussions, query resolution, and Regulatory alignment.
4
Compliance Risk Mitigation
Identified and addressed potential compliance risks proactively to reduce the likelihood of inspection findings, delays, or Regulatory disruptions.
5
Regulatory Operations Management
Delivered end-to-end Regulatory operations support to ensure smooth execution of inspection activities and uninterrupted progress toward market authorization.
Impact
Freyr's support enabled the client to successfully navigate a critical NMPA overseas inspection while strengthening Regulatory compliance, operational readiness, and market access continuity in China.
Regulatory Excellence
- Achieved successful completion of the NMPA overseas inspection
- Ensured alignment with China Regulatory requirements and inspection expectations
- Delivered inspection support with zero compliance flags
- Strengthened audit readiness and Regulatory governance
Faster Submission Execution
- Facilitated timely completion of inspection activities
- Accelerated issue resolution through proactive Regulatory engagement
- Minimized risks associated with inspection delays and non-compliance
Operational Efficiency
- Streamlined inspection planning, coordination, and communication workflows
- Improved collaboration between global stakeholders and Regulatory authorities
- Enhanced visibility into inspection readiness and compliance activities
Business Value
- Maintained uninterrupted market authorization support in China
- Reduced Regulatory risk for a high-priority blood-derived therapy
- Strengthened the client's China market access and commercialization strategy
- Supported long-term Regulatory compliance and business continuity
